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Background: Many patients with rheumatoid arthritis (RA) do not attain remission/low disease activity, remaining
in a moderate disease activity state (MDAS) with ongoing disability and impaired quality of life (QoL). If patients in
persistent MDAS with poor future outcomes could be prospectively identified, they could arguably be treated more
intensively. We evaluated baseline factors predicting function (Health Assessment Questionnaire-Disability Index
[HAQ-DI] scores) and QoL (3-level EuroQol-5 dimensions questionnaire [EQ-5D-3L] index scores) at 12 months in
patients with RA in persistent MDAS in a real-world setting.
Methods: Patients with persistent MDAS (Disease Activity Score for 28-joint count based on erythrocyte
sedimentation rate [DAS28-ESR] 3.2–5.1 on at least two consecutive outpatient appointments over 12 months) were
identified retrospectively from Guy’s Hospital RA Centre and analysed in two groups: (1) biologic naïve at baseline
or (2) receiving/ever received biologics. The baseline timepoint was the second-visit MDAS DAS28-ESR score; the
endpoint was the closest visit to 12 months. Linear regression analyses evaluated relationships between baseline
variables and (1) 12-month HAQ-DI scores, (2) 12-month rank-transformed EQ-5D-3L index scores, (3) 12-month
changes in HAQ-DI scores, and (4) 12-month changes in EQ-5D-3L index scores.
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Results: The analysis included 207 biologic-naïve and 188 biologic-experienced patients. All patients had moderate
disability (mean HAQ-DI 1.21 and 1.46) and impaired QoL (mean EQ-5D-3L index scores 0.52 and 0.50). Many
reported moderate/severe pain (93 and 96%) and showed little change in HAQ-DI and EQ-5D-3L index scores over
12 months. In both biologic-naïve and biologic-experienced groups, multivariate analysis revealed a significant
association between baseline HAQ-DI scores and endpoint HAQ-DI scores (β = 0.67, P < 0.001 and β = 0.76, P <
0.001, respectively), 12-month changes in HAQ-DI scores (both β = − 0.21, P < 0.001), and 12-month EQ-5D-3L index
scores (β = − 0.57, P < 0.001 and β = − 0.29, P = 0.004, respectively). Baseline EQ-5D-3L index scores were significantly
associated with 12-month changes in EQ-5D-3L index scores in both groups (β = − 0.73, P < 0.001 and β = − 0.40,
P = 0.003, respectively).
Conclusions: Patients with RA in persistent MDAS experience substantial ongoing physical disability, poor QoL, and
pain. HAQ-DI is an important predictor of future disability and reduced QoL, supporting current national
recommendations to measure HAQ-DI in routine care.
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The established approach to managing patients with
rheumatoid arthritis (RA) is treat-to-target (T2T) [1]. This
focuses on the gradual up-titration of synthetic disease-
modifying anti-rheumatic drugs (DMARDs), followed by
the introduction of biologics and targeted synthetic
DMARDs, until the goals of sustained remission or a low
disease activity state (LDAS) are attained [2, 3]. In routine
clinical practice, remission and LDAS are often defined as
the attainment of a Disease Activity Score for 28-joint
count based on erythrocyte sedimentation rate (DAS28-
ESR) of < 2.6 and ≥ 2.6 to < 3.2, respectively.
A key challenge in implementing T2T in routine care is
that a substantial minority of patients do not reach remission
or LDAS and instead remain in a moderate disease activity
state (MDAS), defined as a DAS28-ESR of ≥3.2 to ≤5.1. This
was exemplified in two separate observational cohort studies
of patients with early RA. First, in the UK-based Early RA
Study of 2045 patients with DAS28 recorded at least twice
between the first and fifth year of follow-up, 47% had mean
DAS28 scores over time in the MDAS range [4]. Second, in
the North America-based CATCH study, which employed
group-based trajectory modelling, 10% of 1586 patients were
initially in a high disease activity state (HDAS) and only im-
proved to MDAS over 2 years [5].
There is emerging evidence that patients in persistent
MDAS have worse outcomes than those attaining LDAS or
remission, exhibiting higher levels of joint damage [4], worse
function [4, 6], and lower health-related quality of life
(HRQoL) [5]. If it were possible to identify patients in per-
sistent MDAS who are most likely to have poor outcomes,
then an argument could be made for treating such individ-
uals more intensively. Such treatment could include biologics
or targeted synthetic DMARDs, which in the UK are cur-
rently restricted to patients in HDAS (defined as DAS28-
ESR > 5.1) [7], and intensive physical therapy [8].To this end, we undertook a retrospective analysis using
records of patients with RA in persistent MDAS managed
using a T2T approach in a routine UK national health ser-
vice setting. Our primary aim was to identify factors pre-
dicting patient functional outcomes at 12months.
Secondary aims were to identify factors predicting patient
HRQoL at 12months and to characterise pain, disability,
and HRQoL in patients in persistent MDAS.
Methods
Subjects
We retrospectively evaluated patient records from Guy’s
Hospital RA Centre, which maintains an electronic
healthcare record cohort of patients attending routine
rheumatology appointments at Guy’s Hospital (South
London) [9, 10]. Since inception of the database in 2006,
clinician- and patient-reported outcomes, including
DAS28-ESR, Health Assessment Questionnaire-
Disability Index (HAQ-DI) [11] and EuroQol 5-
dimensions 3-level questionnaire index (EQ-5D-3L)
scores (UK value set) [12], have been routinely recorded
for patients at each clinic visit. All patients are managed
in line with T2T recommendations.
No globally accepted definition of persistent MDAS
exists, with previous research in this area using varying
descriptions [4, 6]. In this analysis, we considered pa-
tients to be in persistent MDAS if they had DAS28-ESR
scores of 3.2–5.1 on at least two consecutive outpatient
appointments over a 12-month period. For the purposes
of this study, patients also had to have recorded HAQ-
DI scores at both baseline and final timepoints (to allow
the primary study aim to be addressed).
Patients in persistent MDAS were analysed in two sep-
arate groups: first, those naïve to biologic DMARDs at
baseline and, second, those who were receiving or had
previously received biologic DMARDs. The rationale for
this sub-categorisation of patients was that the next step
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patient groups.
Statistical analysis
For this analysis, the baseline timepoint was the visit at
which patients met our definition of ‘persistent MDAS’.
Thus, the baseline timepoint was the second of two con-
secutive outpatient appointments over a 12-month
period in which each patient had a DAS28-ESR score of
3.2–5.1. The endpoint was the outpatient visit closest to
12 months after the baseline visit.
Linear regression analyses were used to explore rela-
tionships between baseline variables and (1) 12-month
HAQ-DI scores, (2) 12-month EQ-5D-3L index scores,
(3) 12-month changes in HAQ-DI scores, and (4) 12-
month changes in EQ-5D-3L index scores. Rank-
transformed 12-month EQ-5D-3L index scores were
used, as raw 12-month EQ-5D-3L index scores were not
normally distributed. This involved the use of an ordered
quantile normalisation transformation approach, a rank-
based procedure whereby the values of a vector are
mapped to their percentile, which is then mapped to the
same percentile of the normal distribution [13].
Baseline variables evaluated in the linear regression
models comprised age, sex, ethnicity, disease duration,
rheumatoid factor (RF) status, RA therapy (monotherapy
or combination synthetic DMARD therapy or no treat-
ment for biologic-naïve patients; DMARD monotherapy,
biologic monotherapy, or combination synthetic DMARD
and biologic therapy for biologic-experienced patients),
corticosteroid use, ESR, DAS28-ESR, swollen joint
count (SJC), tender joint count (TJC), HAQ-DI score,
Patient Global Assessment of Disease Activity (PtGA),
EQ-5D-3L index score, EQ-5D-3L pain score (question
4 of the EQ-5D-3L), and EQ-5D-3L anxiety/depression
score (question 5 of the EQ-5D-3L). Due to substantial
levels of missing data, we did not include anti-cyclic
citrullinated peptide or C-reactive protein levels in the
linear regression models, opting for RF and ESR to
capture information on serology and the acute-phase
response instead.
Univariate linear regression models included either
(1) 12-month HAQ-DI scores, (2) 12-month rank-
transformed EQ-5D-3L index scores, (3) 12-month
change in HAQ-DI scores, or (4) 12-month change in
EQ-5D-3L index scores as the response variable and
each individual baseline variable as the explanatory vari-
able. Baseline variables with a P-value of < 0.1 in univari-
ate models were subsequently included in multivariate
regression models as explanatory variables.
Correlation coefficients for variables that may have
been affected by strong multicollinearity (DAS28 and its
components; EQ-5D-3L index scores and EQ-5D-3L
pain and depression/anxiety scores) were checked toensure they did not meet the pre-defined threshold of
> 0.7, which would have precluded entry of both variables
into the same model.
For all analyses, P-values of < 0.05 were considered
statistically significant; no multiplicity adjustments were
undertaken. Missing data were not imputed. All analyses
were performed using R (version 3.5.3). Rank-based




From 17,002 patient-visits, we identified 422 patients
with RA who met our criteria for persistent MDAS. Of
these, 395 had HAQ-DI scores at baseline and final
timepoints, and were included in the analysis (207
biologic-naïve and 188 biologic-experienced patients).
In both patient groups, baseline HAQ-DI and EQ-5D-3L
index scores indicated moderate disability and reduced
HRQoL (Table 1). The majority of patients reported mod-
erate or severe pain on the EQ-5D-3L pain scale at baseline
(93% of biologic-naïve and 96% of biologic-experienced
patients). Compared with biologic-naïve patients, biologic-
experienced patients were younger, showed longer RA dur-
ation, were more likely to be RF positive, and had higher
rates of corticosteroid use. They also had higher DAS28-
ESR and HAQ-DI scores and were more likely to report
moderate or severe anxiety/depression at study baseline.
Changes in HAQ-DI scores
Baseline and 12-month mean HAQ-DI scores were similar
in the two patient groups. In biologic-naïve patients, baseline
and 12-month mean HAQ-DI scores were 1.21 ± 0.79
(standard deviation [SD]) and 1.21 ± 0.80, respectively. Many
patients showed substantial changes in HAQ-DI scores over
the follow-up period (Supplementary Fig. 1). A worsening or
improvement in HAQ-DI scores that exceeded the mini-
mum clinically important difference (MCID) of 0.22 units
[14] was observed in 60 (29%) and 58 (28%) patients, respect-
ively. In biologic-experienced patients, baseline and 12-
month mean HAQ-DI scores were 1.46 ± 0.74 and 1.47 ±
0.76, respectively. A worsening or improvement in HAQ-DI
scores that exceeded the MCID of 0.22 units was observed in
56 (30%) and 50 (27%) patients, respectively.
Changes in EQ-5D-3L index scores
As with HAQ-DI scores, baseline and 12-month mean
EQ-5D-3L index scores were similar in both patient
groups. In biologic-naïve patients, baseline and 12-
month mean EQ-5D-3L index scores were 0.52 ± 0.30
(SD) and 0.53 ± 0.30, respectively; mean change in EQ-
5D-3L index scores was 0.02 ± 0.31, reflecting an im-
provement in QoL. In biologic-experienced patients,
baseline and 12-month mean EQ-5D-3L index scores were
Table 1 Baseline characteristics of patients with RA with persistent moderate disease activity




Age (years) 58.5 ± 15.6 55.4 ± 14.1
Female 167 (81) 153 (81)
Ethnicity White 140 (70) 112 (74)
Black 33 (17) 25 (17)
Asian 12 (6) 6 (4)
Mixed 4 (2) 3 (2)
Other 9 (5) 5 (3)
Duration of RA (years) 7.0 ± 9.0 21.1 ± 12.0
RF positive 105 (64) 131 (80)
Anti-CCP positive 69 (54) 65 (59)
Corticosteroids 22 (11) 38 (20)
Treatment: Biologic naïve Monotherapy 99 (52) –
Combination 89 (47) –
None 3 (2) –
Treatment: Biologic experienced DMARD – 51 (30)
Biologic – 25 (15)
DMARD – biologic – 94 (55)
DAS28-ESR 4.0 ± 0.5 4.1 ± 0.5
28-TJC 4.3 ± 4.3 4.9 ± 4.2
28-SJC 2.1 ± 2.8 2.7 ± 2.6
PtGA 50.0 ± 21.8 51.0 ± 21.4
ESR 21.8 ± 16.3 20.0 ± 16.1
HAQ-DI 1.2 ± 0.8 1.5 ± 0.7
EQ-5D-3L index 0.5 ± 0.3 0.5 ± 0.3
EQ-5D-3L pain None 12 (7) 8 (4)
Moderate 135 (79) 153 (82)
Severe 23 (14) 26 (14)
EQ-5D-3L anxiety/depression None 92 (55) 91 (49)
Moderate 64 (38) 87 (47)
Severe 12 (7) 8 (4)
Results are presented as n (%) or mean ± standard deviation. The following data are missing in the biologic-naïve population: ethnicity in 9 patients; disease
duration in 7 patients; RF in 43 patients; anti-CCP in 80 patients; DMARD treatment in 16 patients; TJC/SJC/PtGA in 1 patient; ESR in 6 patients; EQ-5D-3L index
scores in 35 patients. The following data are missing in the biologic-experienced population: sex in 2 patients; ethnicity in 37 patients; RF in 25 patients; anti-CCP
in 78 patients; DMARD treatment in 18 patients; PtGA in 1 patient; ESR in 12 patients; EQ-5D-3L index scores in 1 patient
Abbreviations: CCP cyclic citrullinated peptide antibody, DAS28-ESR Disease Activity Score for 28-joint count based on erythrocyte sedimentation rate, DMARD
disease-modifying anti-rheumatic drug, EQ-5D-3L 3-level EuroQol 5-dimensions questionnaire, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment
Questionnaire-Disability Index, PtGA patient global assessment, RA rheumatoid arthritis, RF rheumatoid factor, SJC swollen joint count, TJC tender joint count
Scott et al. BMC Rheumatology            (2020) 4:63 Page 4 of 100.50 ± 0.26 and 0.49 ± 0.31, respectively; mean change in EQ-
5D-3L index scores was minimal (− 0.005± 0.31). Despite
small changes in mean scores, histograms demonstrated that
many patients showed substantial changes in EQ-5D-3L index
scores over the follow-up period (Supplementary Fig. 1).
Predictors of endpoint HAQ-DI scores
In univariate analysis in the biologic-naïve group, base-
line age, male sex, disease duration, RF, DAS28-ESR,
SJC, PtGA, HAQ-DI, EQ-5D-3L index scores, EQ-5D-3Lpain scores, and EQ-5D-3L anxiety/depression scores all
showed significant associations (P < 0.05) with 12-month
HAQ-DI scores (Table 2). In the biologic-experienced
group, age, corticosteroid use, SJC, PtGA, HAQ-DI, EQ-
5D-3L index scores, EQ-5D-3L pain scores, and EQ-5D-
3L anxiety/depression scores all showed significant
associations (P < 0.05) with 12-month HAQ-DI scores
(Table 3).
In multivariate analysis in both patient groups, only base-
line HAQ-DI score showed a significant association with 12-
Table 2 Association of baseline variables with HAQ-DI and EQ-5D-3L index scores in biologic DMARD-naïve patients
Baseline
variable
12-month HAQ-DI score 12-month change in HAQ-DI
score
12-month EQ-5D-3L score 12-month change in EQ-5D-3L
score
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
β P β P β P β P β P β P β P β P
Age 0.01 0.017 0.00 0.284 0.00 0.084 0.00 0.035 0.00 0.595 – – 0.00 0.849 – –
Male sex −0.36 0.010 −0.19 0.134 −0.01 0.948 – – 0.24 0.182 – – 0.30 0.149 – –
White Ref – – – Ref – – – Ref – Ref – Ref – Ref –
Black 0.25 0.105 – – −0.06 0.547 – – −0.52 0.013 −0.44 0.017 −0.12 0.086 −0.16 0.010
Asian −0.39 0.113 – – −0.15 0.354 – – 0.34 0.246 −0.15 0.571 0.07 0.495 0.06 0.506
Mixed −0.17 0.675 – – −0.04 0.888 – – 0.47 0.329 0.21 0.610 0.24 0.139 0.16 0.268
Other 0.16 0.571 – – 0.17 0.357 – – −0.61 0.100 −0.52 0.095 −0.08 0.523 −0.13 0.207
Disease
duration
0.01 0.037 0.01 0.208 0.01 0.197 – – 0.00 0.941 – – 0.00 0.854 – –
RF positive −0.45 < 0.001 −0.19 0.051 −0.06 0.486 – – 0.07 0.708 – – −0.10 0.102 – –
Corticosteroids −0.02 0.906 – – 0.05 0.685 – – 0.23 0.365 – – 0.30 0.710 – –
DAS28-ESR 0.21 0.048 −0.01 0.881 −0.08 0.254 – – −0.05 0.708 – – 0.05 0.282 – –
Swollen joint
count
−0.06 0.002 −0.02 0.227 −0.01 0.415 – – 0.08 0.006 0.04 0.184 0.00 0.664 – –
Tender joint
count
0.01 0.637 – – 0.00 0.926 – – 0.00 0.853 – – 0.00 0.576 – –
PtGA 0.01 < 0.001 0.00 0.225 0.00 0.008 0.00 0.643 −0.01 < 0.001 0.00 0.502 0.00 0.069 0.00 0.197
ESR 0.00 0.626 – – 0.00 0.971 – – 0.00 0.678 – – 0.00 0.662 – –
DMARD
monotherapy
Ref – – – Ref – – – Ref – Ref – Ref – – –
DMARD
combination
0.05 0.646 – – 0.07 0.340 – – −0.40 0.008 −0.44 0.002 −0.08 0.138 – –
No DMARDs −0.65 0.171 – – −0.10 0.738 – – −0.01 0.989 −0.48 0.300 −0.26 0.160 – –
HAQ-DI 0.79 < 0.001 0.67 < 0.001 −0.21 < 0.001 −0.21 < 0.001 −0.65 < 0.001 −0.57 < 0.001 0.01 0.739 – –
EQ-5D-3L
index
−1.30 < 0.001 −0.45 0.119 0.00 0.977 – – 1.52 < 0.001 0.27 0.527 −0.54 < 0.001 −0.73 < 0.001
EQ-5D-3L
pain




0.34 < 0.001 0.11 0.242 0.003 0.621 – – −0.56 < 0.001 −0.56 0.089 0.10 0.008 −0.04 0.353
β- and P-values are from linear regression models that included endpoint HAQ-DI score, endpoint EQ-5D-3L index score (rank-transformed), 12-month change in
HAQ-DI score or 12-month change in EQ-5D-3L index score as the response variable and each baseline variable as the explanatory variable (univariate model) or
all baseline variables with P-values < 0.1 from univariate analysis (multivariate model); P-values shown in bold are significant (< 0.05)
Abbreviations: DAS28-ESR Disease Activity Score for 28-joint count based on erythrocyte sedimentation rate, DMARD disease-modifying anti-rheumatic drug, EQ-5D-
3L 3-level EuroQol 5-Dimensions questionnaire, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, PtGA Patient Global
Assessment of Disease Activity on a 10 cm visual analogue scale, Ref reference group, RF rheumatoid factor
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being associated with higher 12-month HAQ-DI scores, indi-
cating greater disability (Tables 2 and 3, and Fig. 1). In
biologic-naïve patients, the β-value of 0.67 (standard error
[SE] 0.07) indicated that the 12-month HAQ-DI score was
0.67 units higher per unit increase in baseline HAQ-DI score.
In biologic-experienced patients, the β-value of 0.76 (SE
0.06) indicated that the 12-month HAQ-DI score was 0.76
units higher per unit increase in baseline HAQ-DI score.Predictors of change in HAQ-DI scores
In univariate analysis in the biologic-naïve group, age,
PtGA, and HAQ-DI scores all showed significant associ-
ations (P < 0.05) with 12-month changes in HAQ-DI
scores (Table 2), whereas variables associated with such
changes in the biologic-experienced group were DAS28-
ESR, TJC, PtGA, and HAQ-DI scores (Table 3).
In multivariate analysis in both patient groups, base-
line HAQ-DI score showed a significant association with
Table 3 Association of baseline variables with HAQ-DI and EQ-5D-3L index scores in biologic DMARD-experienced patients
Baseline variable 12-month HAQ-DI score 12-month change in HAQ-DI
score
12-month EQ-5D-3L score 12-month change in EQ-5D-3L
score
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
β P β P β P β P β P β P β P β P
Age 0.01 0.003 0.00 0.554 0.00 0.698 – – 0.00 0.510 – – 0.00 0.510 – –
Male sex −0.06 0.679 – – 0.07 0.468 – – −0.30 0.119 – – 0.01 0.886 – –
White Ref – – – Ref – – – Ref – Ref – Ref – Ref –
Black −0.23 0.173 – – −0.08 0.527 – – 0.12 0.574 – – 0.03 0.620 – –
Asian −0.39 0.218 – – −0.10 0.658 – – 0.17 0.672 – – −0.08 0.542 – –
Mixed −0.43 0.328 – – −0.07 0.813 – – 0.66 0.341 – – 0.05 0.815 – –
Other −0.05 0.888 – – −0.26 0.291 – – 0.51 0.255 – – 0.23 0.106 – –
Disease duration 0.00 0.667 – – 0.00 0.845 – – 0.01 0.395 – – 0.00 0.862 – –
RF positive −0.14 0.342 – – −0.12 0.249 – – 0.12 0.535 – – 0.02 0.730 – –
Corticosteroids 0.31 0.026 0.09 0.369 0.00 0.968 – – −0.12 0.490 – – 0.03 0.572 – –
DAS28-ESR 0.00 0.986 – – −0.14 0.057 0.01 0.891 0.00 0.990 – – 0.09 0.053 0.05 0.269
Swollen joint
count
−0.04 0.049 −0.01 0.391 0.00 0.991 – – 0.04 0.138 – – 0.01 0.510 – –
Tender joint
count
−0.02 0.139 – – −0.02 0.001 −0.03 0.006 0.01 0.572 – – 0.01 0.161 – –
PtGA 0.01 0.014 0.00 0.401 0.00 0.060 0.00 0.421 −0.01 0.028 0.00 0.850 0.00 0.047 0.00 0.293
ESR 0.00 0.628 – – 0.00 0.754 – – 0.00 0.222 – – 0.00 0.774 – –
DMARD Ref – – – Ref – – – Ref – Ref – Ref – Ref –
Biologic 0.11 0.561 – – 0.08 0.530 – – 0.08 0.899 – – −0.04 0.604 – –
DMARD biologic 0.02 0.902 – – −0.01 0.882 – – −0.02 0.899 – – −0.04 0.472 – –
HAQ-DI 0.79 < 0.001 0.76 < 0.001 −0.21 < 0.001 −0.21 < 0.001 − 0.49 < 0.001 −0.29 0.004 0.03 0.283 – –
EQ-5D-3L index −1.08 < 0.001 −0.02 0.949 0.28 0.053 −0.10 0.546 1.61 < 0.001 1.18 0.007 −0.50 < 0.001 −0.40 0.003




0.23 0.019 0.05 0.544 −0.01 0.875 – – −0.54 < 0.001 −0.25 0.058 0.09 0.026 −0.02 0.674
β- and P-values are from linear regression models that included endpoint HAQ-DI score, endpoint EQ-5D-3L index score (rank-transformed), 12-month change in
HAQ-DI score or 12-month change in EQ-5D-3L index score as the response variable and each baseline variable as the explanatory variable (univariate model) or
all baseline variables with P-values < 0.1 from univariate analysis (multivariate model); P-values shown in bold are significant (< 0.05)
Abbreviations: DAS28-ESR Disease Activity Score for 28-joint count based on erythrocyte sedimentation rate, DMARD disease-modifying anti-rheumatic drug, EQ-5D-
3L 3-level EuroQol 5-Dimensions questionnaire, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, PtGA Patient Global
Assessment of Disease Activity on a 10 cm visual analogue scale, Ref reference group, RF Rheumatoid factor
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line HAQ-DI scores predicting greater 12-month reduc-
tions (improved functioning) in HAQ-DI scores (Tables
2 and 3, and Fig. 1). In both biologic-naïve and biologic-
experienced patients, the β-values of − 0.21 (SE 0.05)
and − 0.21 (SE 0.06), respectively, indicated that the 12-
month reduction in HAQ-DI score was 0.21 units
greater per unit increase in the baseline HAQ-DI score.
Significant associations with 12-month changes in HAQ-
DI scores were also observed for age (P = 0.035) in
biologic-naïve patients and for TJC (P = 0.006) in
biologic-experienced patients; the small β-values (0.005
and − 0.03, respectively) indicated uncertain clinical rele-
vance for these statistical associations.Predictors of endpoint EQ-5D-3L index scores
In univariate analysis in both patient groups, PtGA, HAQ-
DI, EQ-5D-3L index scores, EQ-5D-3L pain scores, and
EQ-5D-3L anxiety/depression scores all showed signifi-
cant associations (P < 0.05) with 12-month EQ-5D-3L
index scores (Tables 2 and 3; Fig. 2). In the biologic-naïve
group, Black ethnicity, the use of combination DMARD
therapy, and SJC also showed significant associations.
In multivariate analysis, baseline HAQ-DI scores were
significantly associated with 12-month EQ-5D-3L index
scores in both biologic-naïve (β = − 0.57; SE 0.10) and
biologic-experienced patients (β = − 0.29). It was not
possible to clinically interpret the β-values from the re-
gression models because of the rank-transformation of
Fig. 1 Baseline vs. 12-month HAQ-DI scores in biologic-naïve (a, b) and biologic-experienced (c, d) patients. Scatterplots show baseline Health
Assessment Questionnaire-Disability Index (HAQ-DI) scores vs. 12-month HAQ-DI scores or 12-month change in HAQ-DI scores for biologic-naïve
(N = 207) and biologic-experienced (N = 188) patients
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5D-3L index scores had significant associations with
Black ethnicity and combination DMARD therapy in
biologic-naïve patients and with baseline EQ-5D-3L
index scores in biologic-experienced patients.
Predictors of change in EQ-5D-3L index scores
In univariate analysis in both patient groups, EQ-5D-3L
index scores, EQ-5D-3L pain scores, and EQ-5D-3L anx-
iety/depression scores all showed significant associations
(P < 0.05) with 12-month changes in EQ-5D-3L index
scores (Tables 2 and 3; Fig. 2). PtGA also showed a sig-
nificant association in the biologic-experienced group.
In multivariate analysis, baseline EQ-5D-3L scores were
significantly associated with 12-month changes in EQ-5D-
3L index scores in both patient groups. In biologic-naïve
patients, the β-value of − 0.73 (SE 0.14) indicated that the
12-month decrease in EQ-5D-3L index scores was 0.73
units more per unit increase in the baseline EQ-5D-3Lindex score. In biologic-experienced patients, the β-value of
− 0.40 (SE 0.13) indicated that the 12-month decrease in
EQ-5D-3L index scores was 0.40 units more per unit in-
crease in the baseline EQ-5D-3L index score. In biologic-
naïve patients, Black ethnicity also showed a significant
association with 12-month changes in EQ-5D-3L index
scores (β = − 0.16; P = 0.010).
Discussion
Our retrospective analysis of patients with persistent
MDAS in a real-world, T2T setting has three key find-
ings. First, it shows HAQ-DI is a key predictor of pa-
tients’ future functional status and HRQoL, with
baseline HAQ-DI scores significantly associated with 12-
month HAQ-DI and EQ-5D-3L index scores in both
biologic-naïve and biologic-experienced patients. Sec-
ond, it supports existing research indicating that MDAS
is not a benign disease activity state; many patients eval-
uated in this study had substantial ongoing impaired
Fig. 2 Baseline vs. 12-month EQ-5D-3L index scores in biologic-naïve (a, b) and biologic-experienced (c, d) patients. Scatterplots show baseline
EuroQol-5 dimensions questionnaire, 3-level version (EQ-5D-3L) index scores vs. 12-month EQ-5D-3L index scores or 12-month change in EQ-5D-
3L index scores for biologic-naïve (N = 207) and biologic-experienced (N = 188) patients
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ongoing unmet need to address pain in patients with
RA; over 90% of patients reported moderate or severe
pain when assessed using the EQ-5D-3L. Overall, these
findings support the T2T strategy of aiming for remis-
sion/LDAS [2, 3] and the current UK National Institute
for Health and Care Excellence (NICE) guidelines advo-
cating use of the HAQ-DI in routine care [15]. Achiev-
ing MDAS alone appears insufficient to optimise pain
relief, physical function, and HRQoL.
Over 12 months, mean HAQ-DI scores were both rela-
tively high and relatively static in patients with MDAS.
This finding is consistent with data from the Yorkshire
Early Arthritis Register, which showed that persistent
MDAS was associated with persistently high HAQ-DI
scores in early RA [6]. However, a minority of individ-
uals did demonstrate large changes in their HAQ-DI
scores, reflecting evidence that individual patients havedifferent HAQ-DI trajectories, both in early disease [16]
and in persistent MDAS after biologic therapy [17]. An
associated finding in our study was that initial HAQ-DI
scores strongly predicted final HAQ-DI scores, patients
with worse baseline function tending to have worse
function at study endpoint. This finding reflects the con-
siderable evidence that baseline HAQ-DI scores are im-
portant predictors of subsequent outcomes, including
future disability. Research on HAQ-DI as a predictor of
outcomes has been mainly performed in early RA co-
horts [18–21], though there is evidence that baseline
HAQ-DI scores are also predictors in established RA
[22]. Our further finding that higher baseline HAQ-DI
scores were significantly associated with greater 12-
month reductions in HAQ-DI scores, which appears
counterintuitive, is most likely explained by ‘regression
to the mean’. This well-established and ubiquitous statis-
tical phenomenon occurs when unusually large or small
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that are closer to the mean [23], and is seen throughout
studies using repeated measures, including birthweight
of subsequent childbirths [24], blood pressure [25], bone
mineral density scores [26] and cholesterol levels [27].
We found that most MDAS patients (93 and 96% of bio-
logic DMARD-naïve and biologic DMARD-experienced pa-
tients, respectively) had moderate to severe pain on the
EQ-5D-3L pain scale at baseline. This supports existing pa-
tient survey data highlighting that pain is a significant un-
met need for patients with RA, with many patients
reporting pain to be their preferred area for improvement
in the management of their disease [28–30]. Pain in people
with RA is a multidimensional experience driven by a broad
range of factors, including disease activity, pain pathway
sensitisation, joint damage, and the health beliefs of patients
[31]. The cornerstone of pain management lies in its assess-
ment, with Chua et al. [32] recommending the collection of
pain scores at all clinic assessments. Our data support their
suggestion, and further underline the importance of im-
proving how pain is managed in people with RA.
Our study has several strengths. These include the real-
life T2T clinical setting, the focus on a previously poorly
studied patient population in persistent MDAS, and the
comprehensive prospective capture of clinical data over an
extended period. It also has several limitations. First, the
use of data from a single centre resulted in a relatively lim-
ited sample size. In addition, these data may not be repre-
sentative of all rheumatology centres in the UK. Small
sample sizes are an inevitable consequence of single-centre
studies, since the numbers of patients in specific disease ac-
tivity groups are likely to be restricted. However, single cen-
tres can also achieve a consistent management approach,
which may be diluted in multicentre observational studies.
Second, as these data were captured in a real-life setting
when patients routinely attended the rheumatology clinic
rather than scheduled study visits, there was also some vari-
ability in the times at which outcome variables were mea-
sured. Such variability is unavoidable in real-life settings.
Third, pain was assessed using the EQ-5D-3L pain scale,
which only evaluates one facet of a multidimensional prob-
lem using a limited number of pain categories.
Conclusion
The HAQ-DI is an important predictor of future func-
tion and HRQoL. Our study underlines the need to sup-
plement disease activity assessments with HAQ-DI
measurements (in-line with existing NICE guidelines), to
provide important insight into which patients are likely
to demonstrate poor future function and reduced
HRQoL. It also provides further evidence that persistent
MDAS is not a ‘benign’ disease activity state, with many
patients in our study experiencing substantial physical
disability and poor HRQoL alongside high pain levels.Supplementary information
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gend: Histograms show 12-month changes in DAS28-ESR, HAQ-DI, and
EQ-5D-3L index scores in biologic-naïve (N = 207) and biologic-
experienced (N = 188) patients.
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